Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
André Richters, Shelby K. Doyle, David B. Freeman, et al.
Cell chemical biology (2020) Vol. 28, Iss. 2, pp. 134-147.e14
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Advances in targeting ‘undruggable’ transcription factors with small molecules
Matthew J. Henley, Angela N. Koehler
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 9, pp. 669-688
Closed Access | Times Cited: 264
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 163
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 141
Targeting transcription cycles in cancer
Stephin J. Vervoort, Jennifer R. Devlin, Nicholas Kwiatkowski, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 5-24
Closed Access | Times Cited: 102
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 46
The Renaissance of Cyclin Dependent Kinase Inhibitors
Tobias Ettl, Daniela Schulz, Richard J. Bauer
Cancers (2022) Vol. 14, Iss. 2, pp. 293-293
Open Access | Times Cited: 45
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy
Zhenfeng Shi, Lei Tian, Taotao Qiang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6390-6418
Closed Access | Times Cited: 40
Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer
Jiacheng Li, Ting Liu, Yuanli Song, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 11034-11057
Closed Access | Times Cited: 39
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
Lanshu Xiao, Yi Liu, Hui Chen, et al.
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 24
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 15
Relocalizing transcriptional kinases to activate apoptosis
Roman C. Sarott, Sai Gourisankar, Basel A. Karim, et al.
Science (2024) Vol. 386, Iss. 6717
Closed Access | Times Cited: 13
Discovery of a highly potent, selective, and stable d-amino acid-containing peptide inhibitor of CDK9/cyclin T1 interaction for the treatment of prostate cancer
Zhen Xu, Yifei Geng, Lixia Guan, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117248-117248
Closed Access | Times Cited: 1
Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer
Bengul Gokbayrak, Umut Berkay Altıntaş, Shreyas Lingadahalli, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 11651-11674
Closed Access | Times Cited: 54
Report of the First International Symposium on NUT Carcinoma
Christopher A. French, Michael L. Cheng, Glenn J. Hanna, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 12, pp. 2493-2505
Open Access | Times Cited: 37
Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
Theodora A. Constantin, Kyle K. Greenland, Anabel Varela‐Carver, et al.
Oncogene (2022) Vol. 41, Iss. 24, pp. 3303-3315
Open Access | Times Cited: 29
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers
David B. Freeman, Tamara D. Hopkins, Peter Mikochik, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15629-15647
Open Access | Times Cited: 21
Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives
Si Ha, Jiacheng Zhu, Hua Xiang, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 8, pp. 109192-109192
Closed Access | Times Cited: 17
Androgen receptor cofactors: A potential role in understanding prostate cancer
Xiang Li, Haojun Xiong, Xingzhu Mou, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116338-116338
Open Access | Times Cited: 6
Oncogenic dysregulation of pre‐mRNA processing by protein kinases: challenges and therapeutic opportunities
Chiara Naro, Pamela Bielli, Claudio Sette
FEBS Journal (2021) Vol. 288, Iss. 21, pp. 6250-6272
Open Access | Times Cited: 36
Chemical inhibitors of transcription-associated kinases
Kevin C. Clopper, Dylan J. Taatjes
Current Opinion in Chemical Biology (2022) Vol. 70, pp. 102186-102186
Open Access | Times Cited: 26
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
Steven Sher, Ethan C. Whipp, Janek S. Walker, et al.
Leukemia (2022) Vol. 37, Iss. 2, pp. 326-338
Open Access | Times Cited: 25
SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer
Lifeng Lin, Kaixuan Shi, Shaoqing Zhou, et al.
Oncogene (2022) Vol. 41, Iss. 12, pp. 1767-1779
Closed Access | Times Cited: 21
Design, synthesis, and biological evaluation of novel 4,4′-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer
Gui‐Ping Gao, Jiayi Li, Yin Cao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115858-115858
Closed Access | Times Cited: 12
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer
Fu Gui, Baishan Jiang, Jie Jiang, et al.
Science Advances (2025) Vol. 11, Iss. 17
Closed Access
Page 1 - Next Page

Scroll to top